Xencor is trading at $24.42, up +5.30%, with broader biotech strength as context; no clear Xencor-specific announcement explains today’s move.
- XBI is up 2.10%, amid reported M&A activity and positive clinical-trial sentiment.
- Xencor recently scheduled an October 26 webcast to discuss XmAb819 Phase 1 results ahead of an ESMO presentation; available reporting does not establish the upcoming update as the cause of today’s gain.